[Federal Register Volume 89, Number 74 (Tuesday, April 16, 2024)]
[Notices]
[Pages 26929-26930]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-07942]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993--Customer Experience Hub
Notice is hereby given that, on January 11, 2024, pursuant to
section 6(a) of the National Cooperative Research and Production Act of
1993, 15 U.S.C. 4301 et seq. (``the Act''), The Customer Experience Hub
(``CX Hub'') has filed written notifications simultaneously with the
Attorney General and the Federal Trade Commission disclosing (1) the
identities of the parties to the venture and (2) the nature and
objectives of the venture. The notifications were filed for the purpose
of invoking the Act's provisions limiting the recovery of antitrust
plaintiffs to actual damages under specified circumstances.
Pursuant to section 6(b) of the Act, the identities of the parties
to the venture as of the date of this filing are: AcademyHealth,
Washington, DC; Access to Advanced Health Institute, Seattle, WA;
Acclinate, Inc., Birmingham, AL; Addinex Technologies, Inc., New York,
NY; Advanced BioScience Laboratories, Inc., Rockville, MD; Advanced
Life Technologies LLC, Santa Barbara, CA; Advanced Silicon Group,
Lowell, MA; Altec, Inc., Natick, MA; AmebaGone, Madison, WI; AMK
Technologies of Ohio LLC, Mount Vernon, OH; AN2 Therapeutics, Inc.,
Menlo Park, CA; Angels for Change, Tampa, FL; Applied Research
Associates, Albuquerque, NM; Arizona State University, Tempe, AZ;
Aspire Clinical Intelligence LLC, Grand Forks, ND; Auburn University,
Auburn, AL; Battelle Memorial Institute, Columbus, OH; BB Medical
Surgical, Inc., San Francisco, CA; BCG Federal Corp., Washington, DC;
Better Life Learning LLC, Birmingham, MI; BioAustinCTX, Austin, TX;
BioBridge Global, San Antonio, TX; BioCircuit Technologies, Atlanta,
GA; BioLum Sciences LLC, Dallas, TX; Biomotivate, Pittsburgh, PA;
Biosortia Microbiomics, Dublin, OH; Bluehalo Labs LLC, Albuquerque, NM;
Boston Children's Hospital, Boston, MA; Boston Engineering Corp.,
Waltham, MA; Boston Medical Center Corp., Boston, MA; BroadReach Group
LLC, Washington, DC; Burnett School of Medicine at Texas Christian
University, Fort Worth, TX; California Medical Innovations Institute,
San Diego, CA; Cancer Prevention & Research Institute of Texas, Austin,
TX; CarePredict, Inc., Plantation, FL; Children's National Hospital;
Washington, DC; Children's Nebraska, Omaha, NE; ClearCam, Inc., Austin,
TX; Cleveland Clinic, Cleveland, OH; Clinical Research Payment Network,
Elkhart, IL; Clinical Research Strategies LLC, Wexford, PA; Cocrystal
Pharma, Inc., Miami, FL; Cook Children's Health Care System, Fort
Worth, TX; Creare LLC, Hanover, NH; Creatv MicroTech, Inc., Rockville,
MD; Critical Innovations LLC, Lawndale, CA; Cure Rare Disease, Inc.,
Woodbridge, CT; Dallas College, Dallas, TX; Deloitte Consulting LLP,
Arlington, VA; Domestic Monitoring Initiative (DMI), Erie, PA; Durahip
LLC, San Antonio, TX; Eagle Health Analytics LLC, San Antonio, TX;
Egality Sciences LLC, Houston, TX; Eisana, The Woodlands, TX; Elcomm,
Kennesaw, GA; Emory University, Atlanta, GA; emTruth, Glendale, CA;
Fempower Health, Irvington, NY; First Choice Professionals dba First
Health Advisory,
[[Page 26930]]
Scottdale, AZ; Florida Institute for Human & Machine Cognition, Inc.,
Pensacola, FL; GaitIQ, Inc., San Antonio, TX; GelSana Therapeutics,
Inc., Aurora, CO; GeneInfoSec, Boulder, CO; Gener8 LLC, San Jose, CA;
Georgetown University, Washington, DC; Ginkgo Bioworks, Inc., Boston,
MA; Glendor, Inc., Draper, UT; Grant Halliburton Foundation, Inc.,
Dallas, TX; Gwen Lily Research Foundation, Irving, TX; Harmony
Healthcare Solutions, Inc. dba Harmony Health, Sunnyvale, CA;
Healthpointe Solutions, Inc., Austin, TX; HERMTAC LLC, Dallas, TX; ICON
Government and Public Health Solutions, Inc., Blue Bell, PA; Inhance
Digital Corp., Los Angeles, CA; Innovation Incubator, Inc., Bayside,
NY; International Business Machines Corp., Armonk, NY; INVIZA Corp.,
Malden, MA; IOTAI, Inc., Fremont, CA; Irrational Labs, Oakland, CA;
Irving Burton Associates, Silver Springs, MD; JPS Health Network, Fort
Worth, TX; Jubilant Hollisterstier LLC, Spokane, WA; Jurata Thin Film,
Inc., Chapel Hill, NC; K2 Biolabs, Inc., Houston, TX; Kaibab Health,
Sheridan, WY; Knight Technical Solutions LLC, Huntsville, AL; Lazarus
3D, Philomath, OR; Lighthouse XR LLC, Chester, VA; Limax Biosciences,
Inc., Somerville, MA; Locus Biosciences, Morrisville, NC; LSU Health
Science Center: New Orleans, New Orleans, LA; LSU Health Shreveport,
Shreveport, LA; Luna Labs USA LLC, Charlottesville, VA; M3D, Inc., Ann
Arbor, MI; MapHabit, Inc., Atlanta, GA; Maravai Lifesciences, San
Diego, CA; Maryland Technology Development Corp., Columbia, MD; Mass
General Brigham, Somerville, MA; Maxwell Biosciences, Inc., Austin, TX;
MDC Studio, Inc., Baltimore, MD; Medable, Palo Alto, CA; MedVector, El
Segundo, CA; Memsel, Inc., Fort Worth, TX; Moberg Analytics, Inc.,
Philadelphia, PA; Molecular Technologies Laboratories LLC, Columbus,
OH; MRIGlobal, Gaithersburg, MD; National Association of Community
Health Centers, Inc., Bethesda, MD; National Hispanic Health
Foundation, Washington, DC; National Resilience, Inc., San Diego, CA;
National Strategic Research Institute, Omaha, NE; Neurxstem, Inc.,
Columbus, OH; New Horizons Diagnostics Corp., Baltimore, MD; NIRSense,
Inc., Richmond, VA; North Carolina State University, Raleigh, NC;
NXTech, Inc., Patchogue, NY; O3 World LLC, Philadelphia, PA; Oceanit
Laboratories, Inc., Honolulu, HI; OLSF Ventures, Tulsa, OK; Oregon
Bioscience Association, Portland, OR; Orlando Health, Orlando, FL;
Otter Cove Solutions LLC, Gaithersburg, MD; OXOS Medical, Atlanta, GA;
Parkland Center for Clinical Innovation, Dallas, TX; Parkland Health,
Dallas, TX; Patchwise Labs, Alameda, CA; Pennington Biomedical Research
Center, Baton Rouge, LA; Pennsylvania State University--College of
Medicine, Hershey, PA; Phronetik, Inc., Flower Mound, TX; Polaris
Sensor Technologies, Inc., Huntsville, AL; PPD Development LP,
Wilmington, NC; ppxTEX LLC, Jackson, MS; PragmaClin, St. John's,
CANADA; PriMetaz, Boston, MA; Proteios Technology, Inc., Issaquah, WA;
Purdue University, West Lafayette, IN; Qana Therapeutics, Inc., Austin,
TX; QuantaSpec, Inc., Essex Junction, VT; Re:Build Manufacturing,
Framingham, MA; Research Your Health LLC, Plano, TX; Resonantia
Diagnostics, Inc., Dallas, TX; Ridgeline Therapeutics, Houston, TX;
Ronawk, Inc., Overland Park, KS; Rubitection, Pittsburgh, PA; Rubix LS,
Lawrence, MA; Rutgers University, New Brunswick, NJ; Safebeat Rx, Inc.,
Carson, CA; SafeGuard Surgical, Tampa, FL; SafetySpect, Inc., Grand
Forks, ND; Safi Biotherapeutics, Inc., Cambridge, MA; SanaHeal, Inc.,
Boston, MA; Scorpius BioManufacturing, San Antonio, TX; Signature
Science LLC, Austin, TX; Signum Technologies, Inc., Randor, PA; SimX,
Inc., San Francisco, CA; Sonera Magentics, Inc., Berkeley, CA;
Southwest Research Institute, San Antonio, TX; Southwest Texas Regional
Advisory Council, San Antonio, TX; Sozo Dx LLC, Plano, TX; Sparta
Science, San Francisco, CA; SPEAR Human Performance, Inc., Tallahassee,
FL; Spectral Platforms, Duarte, CA; Sperry Medtech, Inc., Springfield,
MA; Stanford Byers Center for Biodesign, Stanford, CA; Stellarray,
Inc., Austin, TX; Swaza, Mountain View, CA; Talis Biomedical Corp.,
Redwood City, CA; Texas A&M Engineering Experiment Station, Bryan, TX;
Texas Biomedical Research Institute, San Antonio, TX; Texas Healthcare
and Bioscience Institute, Austin, TX; Texas Oncology, Dallas, TX; Texas
State University--Translational Health Research Center, San Marcos, TX;
Texas Tech University Health Sciences Center, Lubbock, TX; Texas
Woman's University, Denton, TX; The Geneva Foundation, Tacoma, WA; The
Henry M. Jackson Foundation for the Advancement of Military Medicine,
Bethesda, MD; The Life Raft Group, Wayne, NJ; The Nebraska Medical
Center, Omaha, NE; The University of Texas at Dallas, Richardson, TX;
The University of Texas: M.D Anderson Cancer Center, Houston, TX;
TheraTec, Inc., Horace, ND; TheraVista Health, Brentwood, TN; Thomas
Jefferson University, Philadelphia, PA; Tranexamic Technologies LLC,
Dallas, TX; Ubiros, Inc., Natick, MA; University City Science Center,
Philadelphia, PA; University of California at Riverside, Riverside, CA;
University of Delaware, Newark, DE; University of Hawai'i System,
Honolulu, HI; University of Montana, Missoula, MT; University of
Nebraska Medical Center, Omaha, NE; University of Notre Dame, Notre
Dame, IN; University of Southern California, Los Angeles, CA;
University of Texas at Austin, Austin, TX; University of Texas at San
Antonio, San Antonio, TX; Univox Technical Solutions LLC dba Univox
LLC, Tijeras, NM; Vanderbilt University, Nashville, TN; Varda Space
Industries, Inc., El Segundo, CA; VelocityTX, San Antonio, TX; Verily
Life Sciences LLC, South San Francisco, CA; ViBo Health, Fairfax, VA;
Vivonics, Inc., Bedford, MA; Wake Forest University Health Sciences,
Winston Salem, MA; Weinberg Medical Physics, Inc., Rockville, MD; West-
Tech Materials, Keller, TX; Yuzu Labs Public Benefit Corp., San
Francisco, CA; Zeteo Biomedical LLC, Austin, TX; Zeteo Tech, Inc.,
Sykesville, MD; Zymeron Corp., Durham, NC.
Consistent with 15 U.S.C. 4301(a)(6)(C), (E) and (F), the CX Hub is
a new consortium created in response to requirements of the Advanced
Research Projects Agency for Health (ARPA-H) for the active transition
of health innovation in an expedient, safe, cost-effective, accessible,
and sustainable manner that reaches all Americans. The CX Hub will take
a human-centered approach to develop technologies and health solutions
that will be accessible, desirable, and affordable for all. It will
also take a proactive approach to enhance clinical trials, reach
representative patient populations, and capture outcomes data for
future use leading to better and more equitable health outcomes for
all.
Suzanne Morris,
Deputy Director Civil Enforcement Operations, Antitrust Division.
[FR Doc. 2024-07942 Filed 4-15-24; 8:45 am]
BILLING CODE P